BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19174605)

  • 1. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut.
    Strosberg J; Gardner N; Kvols L
    Neuroendocrinology; 2009; 89(4):471-6. PubMed ID: 19174605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small intestinal neuroendocrine tumors: prognostic factors and survival.
    Bergestuen DS; Aabakken L; Holm K; Vatn M; Thiis-Evensen E
    Scand J Gastroenterol; 2009; 44(9):1084-91. PubMed ID: 19572232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and prognostic features of rectal neuroendocrine tumors.
    Weinstock B; Ward SC; Harpaz N; Warner RR; Itzkowitz S; Kim MK
    Neuroendocrinology; 2013; 98(3):180-7. PubMed ID: 24080744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience.
    Scigliano S; Lebtahi R; Maire F; Stievenart JL; Kianmanesh R; Sauvanet A; Vullierme MP; Couvelard A; Belghiti J; Ruszniewski P; Le Guludec D
    Endocr Relat Cancer; 2009 Sep; 16(3):977-90. PubMed ID: 19470616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
    Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
    Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.
    Chambers AJ; Pasieka JL; Dixon E; Rorstad O
    Surgery; 2008 Oct; 144(4):645-51; discussion 651-3. PubMed ID: 18847650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
    Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
    Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single institution's experience with surgical cytoreduction of stage IV, well-differentiated, small bowel neuroendocrine tumors.
    Boudreaux JP; Wang YZ; Diebold AE; Frey DJ; Anthony L; Uhlhorn AP; Ryan P; Woltering EA
    J Am Coll Surg; 2014 Apr; 218(4):837-44. PubMed ID: 24655881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma.
    Durante C; Boukheris H; Dromain C; Duvillard P; Leboulleux S; Elias D; de Baere T; Malka D; Lumbroso J; Guigay J; Schlumberger M; Ducreux M; Baudin E
    Endocr Relat Cancer; 2009 Jun; 16(2):585-97. PubMed ID: 19240182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
    Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
    Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Survival with Long-Acting Somatostatin Analogues Plus Aggressive Cytoreductive Surgery in Patients with Metastatic Neuroendocrine Carcinoma.
    Deutsch GB; Lee JH; Bilchik AJ
    J Am Coll Surg; 2015 Jul; 221(1):26-36. PubMed ID: 26027502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival.
    Hill JS; McPhee JT; McDade TP; Zhou Z; Sullivan ME; Whalen GF; Tseng JF
    Cancer; 2009 Feb; 115(4):741-51. PubMed ID: 19130464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumors.
    Curran T; Tulin-Silver S; Patel K; Ward S; Schneiderman M; Harpaz N; Schwartz M; Itzkowitz S; Warner RR; Kim MK
    Pancreas; 2011 Nov; 40(8):1253-7. PubMed ID: 21975435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.
    Panzuto F; Nasoni S; Falconi M; Corleto VD; Capurso G; Cassetta S; Di Fonzo M; Tornatore V; Milione M; Angeletti S; Cattaruzza MS; Ziparo V; Bordi C; Pederzoli P; Delle Fave G
    Endocr Relat Cancer; 2005 Dec; 12(4):1083-92. PubMed ID: 16322345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors.
    Boyar Cetinkaya R; Vatn M; Aabakken L; Bergestuen DS; Thiis-Evensen E
    Scand J Gastroenterol; 2014 Jun; 49(6):734-41. PubMed ID: 24679166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors.
    Arnold R; Wilke A; Rinke A; Mayer C; Kann PH; Klose KJ; Scherag A; Hahmann M; Müller HH; Barth P
    Clin Gastroenterol Hepatol; 2008 Jul; 6(7):820-7. PubMed ID: 18547872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
    Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
    Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up.
    Kamp K; Feelders RA; van Adrichem RC; de Rijke YB; van Nederveen FH; Kwekkeboom DJ; de Herder WW
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3060-9. PubMed ID: 24905065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.
    Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK
    Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
    Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
    Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.